Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | ATP4A | P20648 | 1/20 | 0.34 |
| ▸ | ATP4B | P51164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901663 | 0.87 | TLR8 (0.44) | TLR8TLR7MEN1MAPTTSHR | |
| SCHEMBL1900994 | 0.86 | TLR8 (0.39) | ELANETLR8TLR7MEN1MAPT | |
| SCHEMBL1896698 | 0.82 | ELANE (0.38) | ELANETLR8TLR7MEN1MAPT | |
| SCHEMBL1898044 | 0.82 | TLR8 (0.42) | ELANETLR8TLR7MEN1MAPT | |
| SCHEMBL1898389 | 0.80 | TLR7 (0.52) | TLR8TLR7MEN1MAPTTSHR | |
| SCHEMBL1897131 | 0.80 | SLC6A4 (0.37) | TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL1897931 | 0.79 | SLC6A4 (0.39) | TLR8TLR7 | |
| SCHEMBL3996178 | 0.79 | ADORA3 (0.46) | ELANETLR8TLR7 | |
| SCHEMBL1898506 | 0.79 | SRC (0.36) | TLR8TLR7 | |
| SCHEMBL1894483 | 0.79 | TGFBR1 (0.37) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943610-B2 | Pyrazolopyridine-1,4-diamines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1869043-A2 | PYRAZOLOPYRIDINE-1,4-DIAMINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006107853-A2 | PYRAZOLOPYRIDINE-1,4-DIAMINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | IL4, IL2, IL1A | ELANE 2787/4885TLR8 256/4885TLR7 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.